ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,563.58
      0.17%
      US Tech 100
      18,788.00
      0.23%
      Dow Jones
      40,819.46
      -0.10%
      Brent Oil
      72.185
      2.36%
      Bitcoin
      57,676.16
      0.58%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. AnaptysBio Inc (ANAB)

      7. AnaptysBio Inc (ANAB) News

      ANAB

      AnaptysBio (ANAB)

      AnaptysBio Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ANAB
      DateTimeSourceHeadlineSymbolCompany
      08/29/20249:15AMGlobeNewswire Inc.Anaptys Announces Participation in September Investor ConferencesNASDAQ:ANABAnaptysBio Inc
      08/16/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      08/16/202412:07PMEdgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ANABAnaptysBio Inc
      08/16/202412:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      08/14/20244:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
      08/14/20244:41PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANABAnaptysBio Inc
      08/14/20244:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANABAnaptysBio Inc
      08/14/20245:00AMGlobeNewswire Inc.Anaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingNASDAQ:ANABAnaptysBio Inc
      08/05/20244:25PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANABAnaptysBio Inc
      08/05/20244:22PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
      08/05/20244:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
      08/05/20244:15PMGlobeNewswire Inc.Anaptys Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
      07/24/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      07/24/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      07/19/20248:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      07/18/20244:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANABAnaptysBio Inc
      06/18/20248:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      06/18/20248:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      06/18/20248:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      06/18/20248:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      06/18/20248:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
      06/12/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
      05/09/20244:24PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
      05/09/20244:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
      05/09/20244:15PMGlobeNewswire Inc.Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
      05/09/20244:10PMGlobeNewswire Inc.Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
      05/09/20244:05PMGlobeNewswire Inc.Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli RoyaltiesNASDAQ:ANABAnaptysBio Inc
      05/06/202412:59PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANABAnaptysBio Inc
      04/24/20249:00AMPR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:ANABAnaptysBio Inc
      03/11/20244:41PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANABAnaptysBio Inc
       Showing the most relevant articles for your search:NASDAQ:ANAB